Paradigm shift in neuroprotection by NMDA receptor blockade: Memantine and beyond
The DOI matches its Crossref record; 98 of the 98 references it cites were found in a registry or an index.
Abstract
Neuroprotective drugs tested in clinical trials, particularly those that block N-methyl-D-aspartate-sensitive glutamate receptors (NMDARs), have failed miserably in large part because of intolerable side effects. However, one such drug, memantine, was recently approved by the European Union and the US FDA for the treatment of dementia following our group's discovery of its clinically tolerated mechanism of action. Here, we review the molecular basis for memantine efficacy in neurological diseases that are mediated, at least in part, by overactivation of NMDARs, producing excessive Ca(2+) influx through the receptor's associated ion channel and consequent free-radical formation.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The discrepancy in ketamine IC50 values between these two studies might be explained by the concentration of agonist used (50 μM versus 1 mM glutamate), as higher agonist concentrations allow non-competitive antagonists, e.g. ketamine, to block more effectively due to a greater number of open channels”
From Mechanisms of ketamine and its metabolites as antidepressants (2022) · cites this paper as Lipton, 2006
Citations
Cites
Glutamate neurotoxicity and diseases of the nervous system
CHOI, D. (1988) · Neuron · doi:10.1016/0896-6273(88)90162-6 · Cited by 7,972 · cited 1×
“D-aspartate receptor channel blockers memantine, MRZ 2/579 and other amino-alkyl-cyclohexanes antagonise 5-HT(3) receptor currents in cultured HEK293 and N1E-115 cell systems in a non-competitive manner.”
BackgroundAlzheimer's Disease: Genes, Proteins, and Therapy
Selkoe, D. J. (2001) · Physiological Reviews · doi:10.1152/physrev.2001.81.2.741 · Cited by 6,063
Magnesium gates glutamate-activated channels in mouse central neurones
Nowak, L., Bregestovski, P., Ascher, P., Herbet, A., & Prochiantz, A. (1984) · Nature · doi:10.1038/307462a0 · Cited by 4,043
Glycine potentiates the NMDA response in cultured mouse brain neurons
Johnson, J. W., & Ascher, P. (1987) · Nature · doi:10.1038/325529a0 · Cited by 3,139 · cited 1×
“The NR2 family of NMDAR subunits contains a binding site for glutamate, the endogenous agonist, whereas the NR1 subunit binds glycin”
BackgroundVoltage-dependent block by Mg2+ of NMDA responses in spinal cord neurones
Mayer, M. L., Westbrook, G. L., & Guthrie, P. B. (1984) · Nature · doi:10.1038/309261a0 · Cited by 2,893
Excitatory Amino Acids as a Final Common Pathway for Neurologic Disorders
Epstein, F. H., Lipton, S. A., & Rosenberg, P. A. (1994) · New England Journal of Medicine · doi:10.1056/nejm199403033300907 · Cited by 2,658 · cited 1×
“kon Channel + MEM ↔ Channel–MEM (Blocked channel) (1)”
Self-citationMolecular diversity of glutamate receptors and implications for brain function
Nakanishi, S. (1992) · Science · doi:10.1126/science.1329206 · Cited by 2,543
Heteromeric NMDA receptors: molecular and functional distinction of subtypes
Monyer, H., Sprengel, R., Schoepfer, R., Herb, A., Higuchi, M., Lomeli, H., Burnashev, N., Sakmann, B., & Seeburg, P. H. (1992) · Science · doi:10.1126/science.256.5060.1217 · Cited by 2,541
Lipton, S. A., Choi, Y.-B., Pan, Z.-H., Lei, S. Z., Chen, H.-S. V., Sucher, N. J., Loscalzo, J., Singel, D. J., & Stamler, J. S. (1993) · Nature · doi:10.1038/364626a0 · Cited by 2,433
Self-citationNitric oxide mediates glutamate neurotoxicity in primary cortical cultures.
Dawson, V. L., Dawson, T. M., London, E. D., Bredt, D. S., & Snyder, S. H. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.14.6368 · Cited by 2,174
Research works printed but not linked: 5
- Chen, H. -S. V. & Lipton, S. A. in Post Genomic Drug Discovery Research (ed. Huang, Z.) (John Wiley & Sons, Hoboken, NJ (in the press).
- Navia, B. A., Yiannoutsos, C., Ellis, R., Schifitto, G., Nath, A., Shriver, S., Millar, L. & Lipton, S. A. Memantine may prevent further cognitive decline in subjects with AIDS Dementia Complex with detectable CSF HIV RNA. Neurology 64 (Suppl. 1), A247–A238 (2005).
- Lipton, S. A., Rayudu, P. V., Choi, Y. -B., Sucher, N. J. & Chen, H. -S. V. in Prog Brain Res. (eds Mize, V., Dawson, T. M., Dawson, M. & Friedlander, M.) 73–82 (Elsevier, Amsterdam, 1998).
- Káradóttir, R., Cavelier, P., Bergersen, L. H. & Atwell, D. NMDA receptors in oligodendrocyte physiology and pathology. Nature (in the press).
- Micu, I. et al. NMDA receptors mediate Ca accumulation in central nervous system myelin during chemical ischemia. Nature (in the press).
Cited by
Items 701–800 of 943
Zhang, M., Zhang, X.-L., Li, Y., Fan, W.-J., Wang, Y.-H., Hao, M., Zhang, S.-W., & Ai, C.-Z. (2011) · International Journal of Molecular Sciences · doi:10.3390/ijms12095999 · Cited by 5
“3d-qsar study of a series of non-competitive 1,3-dihydrobenzo [b][1,4]diazepine-2-one mglur2/3 antagonists.”
BackgroundMethodInfluentialOpportunities to minimise risk in drug discovery and development
Swinney, D. C. (2006) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.1.7.627 · Cited by 5
“Serendipity contributed to the discovery of a number of first in class drugs including cinacalcet [20,21], memantine [17] and fuzeon [23].”
BackgroundInfluentialExpression of a recombinant Phoneutria toxin active in calcium channels
Souza, I. A., Cino, E. A., Choy, W., Cordeiro, M. N., Richardson, M., Chávez-Olórtegui, C., Gomez, M. V., Prado, M. A. M., & Prado, V. F. (2012) · Toxicon · doi:10.1016/j.toxicon.2012.05.026 · Cited by 5
Preskorn, S., Borges, S., & Flockhart, D. A. (2006) · Journal of Psychiatric Practice · doi:10.1097/00131746-200607000-00006 · Cited by 5
Protein misfolding and its dual role in neurodegeneration and cancer progression
Jamwal, R. S., Sharma, B., Minerva, Gupta, A., Misri, S., Shankaryan, R., Shah, R., & Kumar, R. (2025) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2025.10.001 · Cited by 5
Zhang, D., Jing, X., Ma, R., Li, Z.-Z., Zhang, X., Ding, Y., & Yue, Y. (2025) · Frontiers in Neuroscience · doi:10.3389/fnins.2025.1581758 · Cited by 4
“For example, excessive activation of NMDA receptor-mediated glutamatergic signaling (GRIN1) in early ischemia may lead to intracellular calcium overload and a cascade of apoptotic and necrotic events (Lai et al., 2014; Lipton, 2006).”
Memantine: A Treatment for Alzheimer’s Disease with a New Formulation
Makino, K. M., & Porsteinsson, A. P. (2011) · Aging Health · doi:10.2217/ahe.11.31 · Cited by 5
White Matter Injury After Experimental Intracerebral Hemorrhage
Wagner, K. R. (2013) · Springer eBooks · doi:10.1007/978-1-4614-9123-1_11 · Cited by 4
Iron-Calcium Crosstalk in Neurodegenerative Diseases
Kadian, M., Sharma, G., & Kumar, A. (2022) · Nutritional neurosciences · doi:10.1007/978-981-19-7327-7_6 · Cited by 5
Neuroinflammation and Binge Eating
Asuku, A. O., & Ogungbangbe, G. O. (2024) · Advances in medical diagnosis, treatment, and care (AMDTC) book series · doi:10.4018/979-8-3693-3230-6.ch010 · Cited by 4
Pai, Y. H., Lim, C., Park, K.-A., Cho, H. S., Lee, G., Shin, Y. S., Kim, H., Jeon, B. H., Yoon, S. H., & Park, J. B. (2016) · Korean Journal of Physiology and Pharmacology · doi:10.4196/kjpp.2016.20.4.425 · Cited by 4
“To isolate eNMDAR function, we adopted an eNMDAR selective antagonist, memantine [21,22].”
MethodCNB-001 reduces paraplegia in rabbits following spinal cord ischemia
Lapchak, P. A., Boitano, P. D., Bombien, R. H., Chou, D., Knight, M., Muehle, A., Winkel, M. T., & Khoynezhad, A. B. (2019) · Neural Regeneration Research · doi:10.4103/1673-5374.262598 · Cited by 4
“…effects of treatment with either intravenous CNB-001 (10 mg/kg) or memantine (20 mg/kg) (Chen et al., 1992; Chen and Lipton, 2005; Lapchak, 2006; Lipton, 2006), a noncompetitive low affinity NMDA open-channel antagonist, on behavioral deficits of female rabbits following infrarenal aortic…”
BackgroundThe Efficiency of Multi-target Drugs: A Network Approach
Alberca, L. N., & Talevi, A. (2020) · Human perspectives in health sciences and technology · doi:10.1007/978-3-030-32857-3_3 · Cited by 4
Galantamine Delivery for Alzheimer’s Disease
Sharma, S. (2020) · Sustainable agriculture reviews · doi:10.1007/978-3-030-41838-0_5 · Cited by 4
Ampakines — a promising approach to neuroprotection
Киселев, А. В., Котов, А. С., Mikhaleva, M. G., Stovbun, S. V., & Kotov, S. V. (2022) · S S Korsakov Journal of Neurology and Psychiatry · doi:10.17116/jnevro202212209154 · Cited by 4
Memantine treats psychosis and agitation associated with Moderna COVID-19 vaccine
Siao, W.-H., Chang, F., & Chen, Y.-C. (2023) · Schizophrenia Research · doi:10.1016/j.schres.2023.03.011 · Cited by 4
“Memantine acts as an excitatory neuron modulator and effectively tones down the excessive glutamine activity thus reverse the pathological excitation (Lipton, 2006), reduces the oxidative stress (Dias et al., 2007).”
Bourque, M., Morissette, M., Conquet, F., Charvin, D., & Paolo, T. D. (2023) · Brain Research · doi:10.1016/j.brainres.2023.148349 · Cited by 4
Sharma, M. C., & Sharma, S. (2013) · Journal of Taibah University for Science · doi:10.1016/j.jtusci.2013.12.001 · Cited by 4
de Diego, A. M. G., Lorrio, S., Hernández-Guijo, J. M., Gandía, L., & de Diego, A. M. G. (2012) · Wiley eBooks · doi:10.1002/9781118185537.ch4 · Cited by 4
Random mutagenesis of human serine racemase reveals residues important for the enzymatic activity
Hoffman, H. E., Jirásková, J., Zvelebil, M., & Konvalinka, J. (2010) · Collection of Czechoslovak Chemical Communications · doi:10.1135/cccc2010003 · Cited by 4
PREFORMULATION STUDIES FOR A PARENTERAL SOLUTION OF MEMANTINE
Achim, M., Vlase, L., Iuga, C. A., Georgescu, R., & Sorin (2011) · Cited by 4
Neurotensin and Neurotensin Receptors in health and diseases: A brief review
MITRA, S. P. (2017) · Cited by 4
Ludueña, R. F. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.838393 · Cited by 4
“…6 April 2022 | Volume 15 | Article 838393 glutamate induces oxidative stress in neurons by binding the NMDA receptor, which causes a significant increase in the intracellular concentration of reactive oxygen species, including nitric oxide (Li et al., 2001; Lipton, 2006; Raju et al., 2015).”
BackgroundMechanisms of NMDA Receptor Inhibition by Biguanide Compounds
Zhigulin, A. S., Novikova, A. O., & Barygin, O. I. (2024) · Pharmaceuticals · doi:10.3390/ph17091234 · Cited by 3
“These properties, to a large extent, determine their clinical tolerability [18], making the studies of molecular mechanisms of inhibition extremely important.”
BackgroundADAPT-M: a workflow for rapid, quantitative in vitro measurements of enriched protein libraries
Perez, C. P., DelRosso, N. V., Noland, C. L., Parekh, U., Choe, C. A., Eguchi, R. R., Wen, Q., Fordyce, P. M., & Huang, P. (2026) · Nature Communications · doi:10.1038/s41467-026-75463-1 · Cited by 4
“26).”
Yu, S. P., Gu, X., Jiang, M. Q., Sastry, A., Wu, L., Li, Y., & Wei, L. (2025) · Cells · doi:10.3390/cells14231871 · Cited by 4
“MEM is a low-affinity, uncompetitive, and use-dependent NMDAR antagonist with unique voltage-and Mg 2+ -dependent properties, acting at moderate membrane depolarizations [67].”
The NMDA Receptor Antagonist Memantine Modulates Aging and Stress Resilience
Juozaityte, V., Pregnolato, C., Nørgaard, S., Rausch, D. M., McIntyre, R. L., Gerhart‐Hines, Z., Pers, T. H., Salcini, A. E., & Clemmensen, C. (2025) · Aging Cell · doi:10.1111/acel.70303 · Cited by 3
Delbono, O., Wang, Z., & Messi, M. L. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102999 · Cited by 6
The Bright and Dark Sides of Nitric Oxide in Neurodegenerative Diseases
Buccarello, L., Montagna, C., Matteo, S. D., Mangione, R., Carota, G., Sibbitts, J., Jarošová, R., Lunte, S. M., Lazzarino, G., & Caruso, G. (2026) · Journal of Personalized Medicine · doi:10.3390/jpm16050246 · Cited by 3
Nitric oxide signaling in Alzheimer's disease: A double-edged sword
Wasim, R. (2026) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2026.178986 · Cited by 3
Prantzalos, E. R., Chesser, J. P., Logan, J. S., McLaurin, K. A., Anderson, C. D., Gabbard, J. D., Severson, W. E., Palmer, K. E., Mullins, B. J., Dwoskin, L. P., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-00738-4 · Cited by 3
Sobolevsky, A. I. (2007) · Biochemistry (Moscow) Supplement Series A Membrane and Cell Biology · doi:10.1134/s1990747807010059 · Cited by 4
“On the other hand, iGluR-related excitotoxicity, especially the one mediated by NMDA receptors, contributes to virtually all major neurological disorders and can be suppressed by ion-channel blockers [80, 81].”
Effects of Ionotropic Glutamate Receptor Channel Blockers on the Organization of Sleep in Rats
Ватаев, С. И., Oganesyan, G. A., Гмиро, В. Е., Lukomskaya, N. Y., & Magazanik, L. G. (2014) · Neuroscience and Behavioral Physiology · doi:10.1007/s11055-014-9920-7 · Cited by 3
Ma, L., Tian, M., Sun, Q., Liu, N., Dong, J., Feng, K., Wu, Y., Wang, Y., Wang, G., Chen, W., et al. (2020) · The FASEB Journal · doi:10.1096/fj.202000534r · Cited by 3
Recent trends of theranostic applications of nanoparticles in neurodegenerative disorders
Raikwar, S., & Jain, S. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-85544-0.00008-3 · Cited by 6
Polypharmacology in Drug Design and Discovery—Basis for Rational Design of Multitarget Drugs
Wang, Z., & Yang, B. (2022) · Springer eBooks · doi:10.1007/978-3-031-04998-9_12 · Cited by 3
Memantine in the Treatment of Alzheimer’s Disease
Porsteinsson, A. P., & Cosman, K. M. (2006) · Aging Health · doi:10.2217/1745509x.2.6.891 · Cited by 4
“The development of moderateaffinity NMDA receptor antagonists has produced more promising results [5,12,13,44].”
BackgroundLu, J., Wen, Y., Zhang, L., Zhang, C., Zhong, W., Zhang, L., Yu, Y., Chen, L., Xu, D., & Wang, H. (2015) · Toxicology Research · doi:10.1039/c5tx00012b · Cited by 3
Network Pharmacology and Epilepsy
Talevi, A. (2016) · Methods in pharmacology and toxicology · doi:10.1007/978-1-4939-6355-3_18 · Cited by 3
Structural Correlates of Ionotropic Glutamate Receptor Function
Kristensen, A. S., Hansen, K. B., Wollmuth, L. P., Egebjerg, J., & Traynelis, S. F. (2008) · Humana Press eBooks · doi:10.1007/978-1-59745-055-3_6 · Cited by 3
Stojanović, I. R., Ljubisavljević, S., Stevanović, I. D., Pavlović, R., Cvetković, T., Đorđević, V. B., Pavlovic, D. D., Vojinović, S., & Bašić, J. (2012) · Journal of Medical Biochemistry · doi:10.2478/v10011-012-0030-1 · Cited by 3
“Since many intra- and extracellular molecules may participate in neuronal injury, accumulation of nitrosative stress due to excessive generation of NO appears to be a potential factor, contributing to neuronal cell damage and death (25).”
BackgroundThermodynamics and Binding Kinetics in Drug Discovery
Keserű, G. M., & Swinney, D. C. (2015) · Methods and principles in medicinal chemistry · doi:10.1002/9783527673025.ch16 · Cited by 4
Determination of the binding mechanism of histone deacetylase inhibitors
Meyer‐Almes, F. (2018) · Chemical Biology & Drug Design · doi:10.1111/cbdd.13449 · Cited by 3
“Moreover, rapid reversible dissociation kinetics was shown to reduce mechanismbased toxicity, particularly for membrane- associated receptors (Kapur & Seeman, 2001; Lipton, 2006).”
BackgroundJunho, B. T., & de Oliveira, V. F. (2019) · Archives of Clinical Psychiatry (São Paulo) · doi:10.1590/0101-60830000000218 · Cited by 4
Memantine and Alzheimer's disease
del Río‐Sancho, S. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-815854-8.00032-x · Cited by 4
Di, Z., Guo, Q., & Zhang, Q. (2021) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2021/5370214 · Cited by 3
“*e important role of overactivated glutamate receptors, especially NMDA receptors, in cerebral ischemia/reperfusion injury has attracted wide attention [6, 7].”
BackgroundSwinney, D. C. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108175 · Cited by 3
Shift Shown in Influenza A Adamantane Resistance
Shah, R. C. (2006) · JAMA · doi:10.1001/jama.296.13.1585-b · Cited by 3
Nakamura, T., & Lipton, S. A. (2021) · Springer eBooks · doi:10.1007/978-3-030-57401-7_10041 · Cited by 3
Self-citationPérez‐Sisqués, L., Bhatt, S., Caruso, A., Ahmed, M. U., Gileadi, T. E., Spring, S., Hendy, E., Taylor‐Papadimitriou, J., Cash, D., Clifton, N. E., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.05.28.596232 · Cited by 3
Auvelity as a Potential Treatment for Alzheimer’s Disease
Lepkowsky, C. M. (2022) · Medical Research Archives · doi:10.18103/mra.v10i10.3206 · Cited by 2
New Hybrid Structures Based on Memanthine and Edaravone Molecules
Grigoriev, V. V., Shevtsova, E. F., Aksinenko, A. Y., Veselov, I. M., Горева, Т. В., Gabrel’yan, A. V., & Бачурин, С. О. (2023) · Doklady Biochemistry and Biophysics · doi:10.1134/s1607672923700461 · Cited by 2
Spiriti, J. M., & Wong, C. F. (2024) · Journal of Chemical Theory and Computation · doi:10.1021/acs.jctc.4c00192 · Cited by 2
The diversity of AMPA receptor inhibition mechanisms among amidine-containing compounds
Zhigulin, A. S., Dron, M. Y., Barygin, O. I., & Tikhonov, D. B. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1467266 · Cited by 2
“Memantine is used in the treatment of Alzheimer ’ s disease (Lipton, 2006).”
BackgroundMethodWang, Y., Yang, Y., Wang, A., Shen, C., Tan, S., Liu, C., Zhao, Y., & Qu, X. (2025) · Advanced Science · doi:10.1002/advs.202519561 · Cited by 3
Cholinesterase inhibitors and sexual disinhibition in dementia: a FAERS disproportionality study
Sayion, K. (2026) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-026-05748-1 · Cited by 2
Potential Therapeutic Strategies for Neurodegenerative Diseases
Farooqui, A. A. (2010) · Springer eBooks · doi:10.1007/978-1-4419-6652-0_9 · Cited by 2
Abdel‐Aal, R. A., Farghaly, H. S. M., & Zakaria, A. (2018) · Journal of Current Medical Research and Practice · doi:10.4103/jcmrp.jcmrp_110_18 · Cited by 2
Briels, B., de Graaf, C., & Bender, A. (2020) · Wiley eBooks · doi:10.1002/9781118681121.ch3 · Cited by 2
Panthee, N., Ōno, M., Yamamoto, T., Ikemura, M., Tanaka, T., Itoda, Y., & Suzuki, H. (2020) · Indian Journal of Thoracic and Cardiovascular Surgery · doi:10.1007/s12055-020-01026-8 · Cited by 2
Macedo, B. L., Veloso, M. D., Dias, I. B., Ayub, J. G. M., & Beijamini, V. (2023) · Behavioural Brain Research · doi:10.1016/j.bbr.2023.114834 · Cited by 3
Network-Pharmacology and Central Nervous System Drug Development
Talevi, A. (2024) · AAPS introductions in the pharmaceutical sciences · doi:10.1007/978-3-031-62604-3_9 · Cited by 2
Synthesis of selenium analogs of 1-azabicyclo[3.3.1]nonane
Proshin, A. N., Serkov, I. V., & Бачурин, С. О. (2012) · Doklady Chemistry · doi:10.1134/s0012500812030044 · Cited by 2
Middleton, K., Zhang, G., Nichols, M. R., & George, T. F. (2012) · Molecular Physics · doi:10.1080/00268976.2012.687467 · Cited by 2
Memantine as a neuroprotective agent in early phases of psychosis
Fusar‐Poli, P., Pellegrini, F., & Cortesi, M. (2006) · Medical Hypotheses · doi:10.1016/j.mehy.2006.07.026 · Cited by 2
Poda, S. B., Kobayashi, M., Nachane, R., Menon, V. P., Gandhi, A. S., Budac, D. P., Li, G., Campbell, B. M., & Tagmose, L. (2015) · Assay and Drug Development Technologies · doi:10.1089/adt.2015.649 · Cited by 2
Glutamate in the neurobiology and treatment of dementias
Cosman, K. M., & Porsteinsson, A. P. (2006) · Primary psychiatry · Cited by 3
Targeting Aβ Receptors to Modify Alzheimer’s Disease Progression
Haas, L. T., & Strittmatter, S. M. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802173-6.00008-3 · Cited by 2
Tam, J. H. K., & Pasternak, S. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-801942-9.00004-5 · Cited by 4
Tabary, S. Z., Tabary, P. Z., & Motlagh, A. S. (2022) · PubMed Central · doi:10.22088/cjim.13.2.412 · Cited by 2
“Increase in glutamate concentration leads to an increase in neuronal excitability through these receptors which in turn trigger the process of neuronal apoptosis (6-8).”
BackgroundApproaches to the treatment of visceral pain
Bulmer, D. C., Coelho, A.-M., & Winchester, W. J. (2007) · Drug Discovery Today Therapeutic Strategies · doi:10.1016/j.ddstr.2008.04.003 · Cited by 2
Ionotropic Glutamate Receptors
Meyer, A. H., Fuchs, E. C., & Monyer, H. (2008) · Springer eBooks · doi:10.1007/978-3-540-38918-7_85 · Cited by 2
Redox Pioneer: Professor Stuart A. Lipton
Stamler, J. S. (2013) · Antioxidants and Redox Signaling · doi:10.1089/ars.2013.5388 · Cited by 1
“With colleagues Stamler, Wang, and Larrick, Lipton developed the allosteric drug NitroMemantine, which is designed to target NO specifically to NMDA receptors, and thereby to downregulate excessive receptor activity via active (memantine) and allosteric (S-nitrosylation) site regulation (47, 83).”
Dication Molecules as Tools for Studying Actylcholine and Glutamate Receptors (Review)
Гмиро, В. Е. (2023) · Pharmaceutical Chemistry Journal · doi:10.1007/s11094-023-02951-9 · Cited by 1
Freyssin, A., Carles, A., Moha, B., Rubinstenn, G., & Maurice, T. (2024) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.4c00522 · Cited by 1
Randomized Placebo-Controlled Trial of Memantine for Smoking Cessation (CCCWFU 99311)
Spangler, J. G., Skidmore, E. R., Dressler, E. V. M., Weaver, K. E., Lesser, G. J., Burton, G. V., Esparaz, B. T., Gillett, B., & Shaw, E. G. (2025) · Cancer Control · doi:10.1177/10732748251336416 · Cited by 1
“9 By contrast, mem-antine ’ s antagonism of the NMDAR decreases dopamine receptor transmission, a process that reduces rat self-administration of nicotine.”
InfluentialMemantine loaded micro/nanoscale magnetic motors for the treatment of Alzheimer's Disease
Tezel, G., Öztürk, E., Ulutürk, S., Öztürk, S. C., Reçber, T., Timur, S. S., Nemutlu, E., Kuralay, F., Esendağlı, G., Gürsoy, R. N., et al. (2025) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2025.107043 · Cited by 1
Caviglia, M., Bello, F. D., Santini, C., Migani, S., Quaglia, W., Gobbo, J. D., Matteucci, F., Morelli, M. B., Zeppa, L., Aguzzi, C., et al. (2025) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2025.113035 · Cited by 1
Liu, Y., Li, R., Cheng, H., Wang, Y., Sun, J., & Zhang, M. (2025) · Pharmaceuticals · doi:10.3390/ph18101456 · Cited by 2
“These interactions are consistent with the mechanism proposed for ifen-prodil and related NMDAR-2B selective antagonists, which prevent glutamate/glycine co-agonist binding, and thus block Ca 2+ influx and downstream CaMKII/CREB signaling [60–62].”
Brimonidine and Cimetidine Are Weak NMDA Receptor Ion Channel Blockers
Zhigulin, A. S., Furman, V. V., & Barygin, O. I. (2025) · Journal of Evolutionary Biochemistry and Physiology · doi:10.1134/s0022093025060043 · Cited by 1
“Non-competitive antagonists bind to other sites, located either in the extracellular portion of the NMDA receptor (allosteric antagonists, e.g., ifenprodil [29]) or in the ion channel pore (channel blockers, e.g., magnesium ion [30, 31] or memantine [8]).”
Casby, J., Allen, R. K., de Velasco, E. M. F., & Thayer, S. A. (2026) · Neurotoxicity Research · doi:10.1007/s12640-026-00788-0 · Cited by 1
“To date, no compounds highly selective for GluN2B-containing NMDARs have proved useful for treat - ing neurodegenerative disorders (Lipton 2006 ; Ramírez et al. 2025 ).”
Yu, P., Liu, J., Xu, W., Peng, L., Li, Y., Shao, S., Wang, Y., Qiu, Z., & Yang, H. (2026) · npj Science of Food · doi:10.1038/s41538-026-00812-9 · Cited by 1
“A postsynaptic protein involved in synaptic recognition and plasticity, PSD-95, plays a critical role in linking NMDA receptor activity to NO production and subsequent neurotoxicity 62,63 .”
Nagata, W., & Ishizuka, T. (2026) · Human Cell · doi:10.1007/s13577-026-01381-5 · Cited by 1
“Anti-NMDA receptor antibodies that penetrate the CNS may bind receptors, alter receptor trafficking, or promote receptor overactivation, thereby exacerbating excitotoxic injury [68–70].”
Mathew, N., George, S., Rejimon, P., Orofino, C., Shaikh, A., Mistry, D., Mazahreh, L., Jose, A., Imran, H., Gupta, S. J., et al. (2026) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/j.jpet.2026.104935 · Cited by 1
Torrisi, S. A., Diolosà, L., Aceto, G., Marchetti, C., Geraci, F., Partsinevelos, K., Rizzo, S., Grasso, M., Caraci, F., Bellia, F., et al. (2026) · British Journal of Pharmacology · doi:10.1111/bph.70500 · Cited by 1
“Under these acute stress – induced conditions, memantine would be ineffective given its preferential targeting of extrasynaptic NMDA receptors (Lipton, 2006).”
InfluentialPérez‐Sisqués, L., Bhatt, S. R., Caruso, A., Robb, J. L., Donovan, A. P. A., Bamford, R. A., Torres-Cano, A., Spring, S., Hendy, E., Gileadi, T. E., et al. (2026) · Science Advances · doi:10.1126/sciadv.adq6577 · Cited by 1
“Treatment of Shank2 e6–7 mutant mice at the time of NMDAR overactivity (PND7 to PND21) with a noncompetitive NMDAR antagonist, memantine ( 36 ), rescued the sociability phenotype ( 34 ).”
Medical Treatment: Neuroprotection
Doshi, A. B., & Weinreb, R. N. (2009) · Springer eBooks · doi:10.1007/978-3-540-68240-0_28 · Cited by 1
Medical Treatment: Neuroprotection
Weinreb, R. N. (2016) · Springer eBooks · doi:10.1007/978-3-662-49042-6_28 · Cited by 1
Epigenetics in Child Psychiatry
Elia, J., Kingsley, R. S., Yost, O., Bongiorno, C., Bernacki, C. G., Ambrosini, A. P., Okuyama, M., & Hakonarson, H. H. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-417114-5.00020-6 · Cited by 1
Lin, W.-C., & Licht, S. (2014) · PLoS ONE · doi:10.1371/journal.pone.0112088 · Cited by 1
“Memantine, an open-channel blocker for the N-methyl-Daspartate receptor, is used for the treatment of Alzheimer’s disease [7].”
BackgroundHausner, L., Sartorius, A., Kranaster, L., & Frölich, L. (2011) · Neuropsychiatry · doi:10.2217/npy.11.48 · Cited by 1
¿Estamos estudiando y tratando correctamente la esquizofrenia?
Swerdlow, N. R. (2011) · Psiquiatría Biológica · doi:10.1016/j.psiq.2011.10.010 · Cited by 4
Sudden cardiac death: Role of therapeutic hypothermia
Derwall, M., Fries, M., & Rossaint, R. (2012) · Cited by 1
PHARMACOKINETICS OF INTRAVENOUSLY AND ORALLY ADMINISTERED MEMANTINE IN SWINE
Vlase, L., Achim, M., Muntean, D. M., Adrian Florin, G. A. L., Bodolea, C., & Sorin, E. (2011) · Cited by 1
Nakamura, T., & Lipton, S. A. (2009) · doi:10.1201/9781420073522-11 · Cited by 1
Self-citationA potential combination therapy for traumatic brain injury: 17beta-estradiol and memantine
Lamprecht, M. R. (2015) · doi:10.7916/d85d8qpd · Cited by 1
Pharmacokinetics of Memantine-derivative MN-08 in Rats: A Preclinical Study
Luo, C., Luo, F., Sun, Y., Xu, L., Yu, P., Wang, Y., & Zhang, Z. (2017) · Journal of Pharmaceutical and Biomedical Sciences · Cited by 1
Magnesium in the Central Nervous System: Magnesium and the Yin-Yang interplay in apoptosis
Trapani, V., Mastrototaro, L., & Wolf, F. I. (2011) · Cited by 1
Farooqui, A. A. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816347-4.00007-6 · Cited by 2
Metadata
- Authors
- Lipton, S. A.
- Affiliations
- Sanford Burnham Prebys Medical Discovery Institute (US)
- Corresponding author
- Lipton, Stuart A.
- ORCID
- Lipton, Stuart A.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2006-01-20
- Volume
- 5
- Issue
- 2
- Pages
- 160-170
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W1981238903
- Cited by
- 909
- References
- 98
- Citations by year
- 2026: 39 · 2025: 31 · 2024: 32 · 2023: 31 · 2022: 40 · 2021: 41 · 2020: 51 · 2019: 42 · 2018: 36 · 2017: 40 · 2016: 48 · 2015: 51 · 2014: 47 · 2013: 48 · 2012: 52
- FWCI
- 5.57
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Keywords
- memantine, NMDA receptor antagonists, neuroprotection, Alzheimer's disease, dementia, glutamate excitotoxicity, calcium influx, free radicals, adverse drug reactions, clinical trial failure, NMDA receptor overactivation
- MeSH terms
- Animals, Humans, Memantine, Neurotoxins, Receptors, N-Methyl-D-Aspartate, Excitatory Amino Acid Antagonists, Neuroprotective Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.